Phase III Data Put Zealand's Dasiglucagon On Track, But Behind Others, For Hypoglycemia Rescue

19 Sep 2018

• By Emily Hayes

Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.

Plastic Autoinjector_222700717_1200.jpg — Currently, rescue treatments for severe hypoglycemia need to be reconstituted, but prefilled syringes in autoinjectors may be on the way.

Positive Phase III results across the board for Zealand Pharma AS's dasiglucagon as a ready-to-use prefilled syringe rescue medication for severe hypoclyemia put the drug on track for a US FDA filing in the second half of 2019, but far behind two competing products that are already under review – Eli Lilly & Co.'s needle-free nasal product AMG504-1 and Xeris Pharmaceuticals Inc.'s XeriSol glucagon autoinjector.

Dasiglucagon (glucagon analog stable in liquid formulation) will be delivered in Zealand's ready-to-use HypoPal autoinjector rescue pen. Severe hypoglycemia is...